前列腺癌PET成像的最新进展与开发动态
本文综述了用于提高前列腺癌成像敏感度和特异度的多种PET放射性示踪剂,包括骨亲和剂Na18F及肿瘤特异性化合物11C-胆碱和18F-氟昔洛韦,讨论了其在不同临床情境中的优缺点,并涉及尚未获监管批准的靶向前列腺特异性膜抗原(PSMA)和胃泌素释放肽受体(GRPR)的示踪剂。
要点
- Na18F为骨亲和剂,11C-胆碱和18F-氟昔洛韦为更肿瘤特异性的化合物。
- 综述讨论上述PET示踪剂在前列腺癌男性不同临床情境中的优缺点。
- 涉及尚未获监管批准的靶向PSMA和GRPR的示踪剂。
核心结论
- 多种PET放射性示踪剂已被开发用于提高前列腺癌成像的敏感度和特异度。
- 综述讨论了Na18F、11C-胆碱和18F-氟昔洛韦等示踪剂在不同临床情境中的优缺点。
- 综述涉及尚未获监管批准的靶向PSMA和GRPR的示踪剂。
研究设计与样本
- 综述,检索范围与纳入文献未报告。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
A number of positron emission tomography (PET) radiotracers have been developed to improve the sensitivity and specificity of imaging for prostate cancer. These radiotracers include the bone-seeking agent Na18F as well as more tumor-specific compounds such as 11C-choline and 18F-fluciclovine. In this review, we will discuss the advantages and disadvantages of these PET radiotracers for the imaging of men with prostate cancer across a range of clinical contexts. We will also touch upon radiotracers in late clinical development that have not gained regulatory approval, including those targeted against prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR).
引用
- Rowe SP, Johnson GB, Pomper MG, et al. Recent updates and developments in PET imaging of prostate cancer. Abdom Radiol (NY). 2020. PMID: 32417934. doi:10.1007/s00261-020-02570-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。